Key facts
- Notable investors include Johnson & Johnson Innovation - JLABS, Bioventure.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aphaia Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Aphaia Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aphaia Pharma
Operator of a clinical-stage pharma agency intended to develop proprietary treatment methods targeting metabolic syndrome. The company develops disease-modifying treatments that enable the body's physiological mechanisms to restore endocrine balance and tissue regeneration for improved metabolic health, enabling patients to access treatment for treating syndrome-associated clinical conditions like obesity, diabetes, fatty liver and heart disease.
- Sector
- Healthcare
- HQ
- Zug, Switzerland
- Founded
- 2018
- Website
- aphaiapharma.com/
- Ownership
- Privately Held (backing)
Aphaia Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aphaia Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aphaia Pharma in its N-PORT filings yet. We sweep new filings monthly.